SNX17 and myasthenia gravis: Our findings demonstrate the effective role of SNX17 on muscle strength recovery in MG, and it can be used as a potentially important target for another symptomatic drug therapy besides pyridostigmine bromide which is the classic symptomatic treatment for MG.